Schoppy David W, Sunwoo John B
Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Hematol Oncol Clin North Am. 2015 Dec;29(6):1033-43. doi: 10.1016/j.hoc.2015.07.009. Epub 2015 Oct 20.
Although head and neck squamous cell carcinoma has traditionally been considered to be a very immunosuppressive, or at least nonimmunogenic, tumor type, recent results from clinical studies of immune checkpoint blockade strategies have led to resurgence in the enthusiasm for immunotherapeutic approaches. Additional strategies for immunotherapy that are under active investigation include enhancement of cetuximab-mediated antibody-dependent cell-mediated cytotoxicity, tumor vaccines, and engineered T cells for adoptive therapy. All of these studies have early-phase clinical trials under way, and the next several years will be exciting as the results of these studies are reported.
尽管头颈部鳞状细胞癌传统上被认为是一种免疫抑制性很强、或者至少是非免疫原性的肿瘤类型，但免疫检查点阻断策略的临床研究近期结果已使人们对免疫治疗方法的热情再度高涨。正在积极研究的其他免疫治疗策略包括增强西妥昔单抗介导的抗体依赖性细胞介导的细胞毒性、肿瘤疫苗以及用于过继性治疗的工程化T细胞。所有这些研究都在进行早期临床试验，随着这些研究结果的报告，未来几年将会令人兴奋。
